PB 32 of 2012

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 3)

National Health Act 1953

___________________________________________________________________________

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.

Dated  26 April 2012

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

___________________________________________________________________

1 Name of Instrument

(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 3).

(2)                This Instrument may also be cited as PB 32 of 2012.

2       Commencement

  This Instrument commences on 1 May 2012.

3 Amendments to PB 79 of 2011

  Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).

Schedule 1 Amendments

[1]     Schedule 1 Part 1, entry for Carboplatin in the form Solution for I.V. injection 50 mg in 5 mL with manner of administration Injection

omit:

[2]     Schedule 1 Part 1, entry for Cisplatin

omit:

[3]     Schedule 1 Part 1, entry for Doxorubicin in the form Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial with manner of administration Injection/intravesical

omit:

[4]     Schedule 1 Part 1, entry for Doxorubicin

omit:

[5]     Schedule 1 Part 1, after entry for Doxorubicin - Pegylated Liposomal in the form Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL with manner of administration Injection and brand Caelyx

insert in the columns in the order indicated:

[6]     Schedule 1 Part 1, after entry for Doxorubicin - Pegylated Liposomal in the form Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL with manner of administration Injection and brand Caelyx

insert in the columns in the order indicated:

[7]     Schedule 1 Part 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 10 mg in 5 mL with manner of administration Injection/intravesical

omit:

[8]     Schedule 1 Part 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 20 mg in 10 mL with manner of administration Injection/intravesical

omit:

[9]     Schedule 1 Part 1, entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL with manner of administration Injection

omit:

substitute:

[10]  Schedule 1 Part 1, entry for Mitozantrone

omit:

[11]  Schedule 1 Part 1, entry for Mitozantrone in the form Injection 25 mg (as hydrochloride) in 12.5 mL with manner of administration Injection

omit:

[12]  Schedule 1 Part 1, entry for Oxaliplatin in the form Powder for I.V. infusion 100 mg with manner of administration Injection

omit:

[13]  Schedule 1 Part 1, entry for Vincristine in the form I.V. injection containing vincristine sulfate 1 mg in 1 mL with manner of administration Injection

omit:

[14]  Schedule 2, entry for Ondansetron in the form I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL with manner of administration Injection

omit:

[15]  Schedule 2, entry for Ondansetron in the form I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL with manner of administration Injection

omit:

[16]  Schedule 3, omit entry for WA

[17]  Schedule 5, before entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. with manner of administration Injection and brand Hospira Pty Ltd

insert:

[18]  Schedule 5, entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. with manner of administration Injection and brand Hospira Pty Ltd

omit from the column headed ‘Listed Drug’:

Bleomycin

[19]  Schedule 5, entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. with manner of administration Injection and brand Hospira Pty Ltd

omit from the column headed ‘Form’:

Powder for injection containing bleomycin sulfate 15,000 I.U.

[20]  Schedule 5, entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. with manner of administration Injection and brand Hospira Pty Ltd

omit from the column headed ‘Manner of Administration’:

Injection

Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.